Details
The document's own metadata, straight from the source system.
- Topics
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Stance breakdown
Who commented
Breakdown by commenter type.
Comments over time
Weekly arrivals, stacked by stance.
Support × commenter type
How each type splits across stance.
Issues raised
The docket's canonical issues. Select one to browse its comments.
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
- Jul 17, 2026Comment from Intellicite LabsSupportBusiness📎 Attachment
Melinda B. Chu, CEO of Intellicite Labs, submits a technical roadmap outlining a long-term research agenda for AI-enabled regulatory science and pharmaceutical development. The submission supports the modernization of regulatory science by proposing a computational ecosystem to improve evidence generation, drug discovery, and clinical development.
Read comment → - Jul 15, 2026Comment from Intellicite LabsSupportBusiness📎 Attachment
Melinda B. Chu, CEO of Intellicite Labs, submits a technical proposal advocating for a Multi-Domain Similarity Assessment (MDSA) framework to support the FDA's Expedited Investigational New Drug (IND) Pilot Program. The proposal suggests a structured methodology to evaluate transferable evidence across multiple domains to reduce nonclinical study duplication and accelerate first-in-human studies while maintaining sponsor responsibility.
Read comment →